ASH 2014 Series Coverage

by David Wallace PV Reporter covering the American Society of Hematology (ASH) 2014 conference in a series format For me personally, highlights go beyond the research that was presented (ASH 2014 Outside the Box, addresses that in detail).  It was about meeting friends…old and new (in person), attending the MPN Heroes Awards Presentation, the excitement […]

ASH 2013 News on MPNs

This update is provided by the MPN Research Foundation  This year’s American Society of Hematology (ASH) meeting provided a bittersweet update on the progress of JAK inhibition therapy in the MPNs. As many readers already know, the Sanofi JAK inhibitor, which had completed Phase 3 trials and was well on its way to the FDA […]

CALR Mutated Essential Thrombocythemia is a distinct disease

polycythemia vera blood cells

JAK2 or CALR mutation status defines subtypes of ET with substantially different clinical course and outcomes Key Points JAK2 (V617F) mutated essential thrombocythemia and polycythemia vera are different phenotypes in the evolution of a single neoplasm CALR mutated essential thrombocythemia is a distinct disease entity not only at molecular level but also with respect to clinical outcomes Abstract Patients with […]

The American Society of Hematology (ASH) Annual Meeting and Exposition 2013

Myeloproliferative Neoplasms ASH 2013

2013 ASH Annual Meeting and Exposition- KEY ABSTRACTS for Myeloproliferative Neoplasms December 7-10, 2013 – Ernest N. Morial Convention Center, New Orleans, LA   Myeloproliferative Neoplasms Absracts Frequent Mutations in the Calreticulin Gene CALR in Myeloproliferative Neoplasms The Genomic Landscape of Myeloproliferative Neoplasms: Somatic Calr Mutations in the Majority of JAK2-Wildtype Patients Increased Platelet Thrombus Formation Under Flow […]

error: Content is protected !
Malcare WordPress Security